Genmab — Marts 2017
-
Det blev 1406. Nordea doblede lige købet.
-
TheNote...Jeg syntes ikke, at store spring under auktionerne den ene eller anden vej i Genmab er så usædvanligt.
-
Det har jeg observeret mange gange.
-
Jeg har faktisk aldrig rigtigt forstået meningen med det. Faktisk slutter kursen næsten altid omkring den kurs auktionen blev indledt på.
-
Det må man sige.
-
Kan nogen opklare det her: I Seeking Alpha's Earnings Call Transcript står flg.: "Excitingly, the Phase III Maia study, evaluating the effect of daratumumab, carfilzomib and dexamethasone alone and frontline multiple myeloma as also finished patient recruitment in December last year and an interim analysis for that study is expected to read out in 2018."
-
ja han har godt nok fået en skidt start i embedet. Mildest talt ikke meget det lykkes for ham at få igennem
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind